Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
종목 코드 PRPO
회사 이름Precipio Inc
상장일Jul 18, 2000
CEOMr. Ilan Danieli
직원 수54
유형Ordinary Share
회계 연도 종료Jul 18
주소4 Science Park
도시NEW HAVEN
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호06511
전화12037877888
웹사이트https://www.precipiodx.com/
종목 코드 PRPO
상장일Jul 18, 2000
CEOMr. Ilan Danieli
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음